Accendra Health (ACH) Q4 2025 earnings review
Rough Start as Standalone: Guidance Resets Lower
Accendra Health (formerly Owens & Minor) begins its journey as a pure-play 'Patient Direct' company with a stumbling block. While Q4 revenue grew 2% to $709M, profitability deteriorated with Adjusted EBITDA falling 12% YoY. The completion of the P&HS business sale provided $342M in cash, but the forward outlook is bearish: FY26 guidance implies a ~6% revenue decline and ~8% EBITDA contraction compared to 2025 actuals, largely driven by the termination of a commercial payor contract. The company remains highly leveraged with Net Debt/EBITDA >5x.
🐂 Bull Case
The sale of the Products & Healthcare Services (P&HS) business closed on Dec 31, generating ~$342M in proceeds. Cash on hand jumped to $282M (vs $27M in Q3), providing a buffer for debt service and operational investments.
Despite earnings headwinds, the company generated nearly $100M in Free Cash Flow in FY25 and guides for $90-110M in FY26. This stability is critical for deleveraging efforts.
🐻 Bear Case
FY26 guidance signals a reversal of growth. Revenue is guided to $2.55-2.65B (down from $2.76B in 2025), and EBITDA is guided to $335-355M (down from $375M). The loss of a commercial payor contract is a significant drag.
Q4 Adj. EBITDA margin compressed by 200 basis points YoY (12.7% vs 14.7%). With revenue shrinking next year, operating leverage will likely remain negative.
⚖️ Verdict: 🔴
Bearish. The 'new chapter' narrative is undermined by immediate guidance for revenue and profit contraction. High leverage (~5x) leaves little room for error as they navigate the loss of a key payor contract.
Key Themes
Commercial Payor Contract Termination
Hidden in the footnotes and implied by the guidance bridge is a major headwind: a 'contract termination with a commercial Payor.' This event triggered a $4.8M equipment sale gain in Q4 but is the primary culprit behind the projected ~$160M revenue drop for FY26. This raises concerns about the stickiness of the remaining customer base.
Profitability Under Pressure
Q4 Adjusted EBITDA fell 12% YoY to $90M despite a 2% increase in sales. This margin deterioration (12.7% vs 14.7% prior year) indicates rising costs or pricing pressure in the core Patient Direct business. FY26 guidance assumes EBITDA margins remain suppressed at ~13% (based on midpoints).
Balance Sheet Reset
The P&HS sale was a necessary strategic move to fix the balance sheet. Cash balances increased 10x sequentially to $282M. However, gross debt remains massive at ~$2.05B. Net debt stands at ~$1.77B, implying a leverage ratio of ~5.1x on 2026 EBITDA guidance ($345M). Deleveraging will be slow with only ~$100M in annual FCF.
Pure-Play Home Health Focus
By shedding the distribution business, Accendra is now 100% focused on the higher-margin, faster-growing 'Patient Direct' market (Apria/Byram). While the immediate financial results are mixed, this streamlined structure should theoretically allow for better operational focus and 'collection rate improvements' cited in their outlook bridge.
Restructuring Costs Persist
Adjusted results exclude significant noise: $18M in exit/realignment charges and $96M in acquisition-related/intangible amortization charges for FY25. The gap between GAAP Net Loss ($102M from cont. ops) and Adj Net Income ($80M) remains wide, complicating the evaluation of 'true' earnings power.
Other KPIs
Decelerating. Down 12% YoY from $102.5M in Q4 2024. The decline occurred despite higher revenue, highlighting a negative mix shift or cost escalation in the quarter.
Stable. Slight increase from $96.4M in FY24. Defined as Adj EBITDA minus Capex, Interest, and transaction adjustments. The company is converting ~26% of EBITDA into Free Cash Flow, a ratio that needs to improve to handle the debt load.
Improved from a massive loss of $(331.9)M in Q4 2024 (which was driven by a goodwill impairment). However, the company remains GAAP unprofitable even without the impairment noise.
Guidance
Reversing. Midpoint ($2.60B) implies a 5.9% decline vs FY25 revenue of $2.76B. This is a significant negative surprise for a 'growth' pivot, attributed to the loss of a large commercial customer.
Reversing. Midpoint ($345M) implies an 8% decline vs FY25 ($375M). Margins are expected to remain flat to down. This contradicts the narrative of a 'higher quality of earnings' post-separation.
Stable. Consistent with FY25 ($98M) and FY24 ($96M). While stability is good, the lack of growth in cash flow slows the pace of balance sheet repair.
Key Questions
Commercial Payor Loss Details
You referenced a contract termination with a commercial payor in the footnotes. What percentage of revenue and EBITDA did this client represent, and are there risks of further attrition among top clients?
Cost Structure Realignment
With revenue guiding down ~6% for 2026, what specific actions are being taken to right-size the SG&A base to protect margins? Why is EBITDA contracting faster than revenue?
Debt Paydown Strategy
With $282M in cash and ~$100M in annual FCF, but over $2B in debt, what is the target leverage ratio and timeline? Will cash be used for debt retirement or acquisitions?